Memorial Sloan Kettering Cancer Center
ASCO 2022 DESTINY-Breast04: Trastuzumab Deruxtecan vs. Treatment of Physician’s Choice in Pts With HER2-Low Unresectable/Metastatic BC
By
ecancer
FEATURING
Shanu Modi
By
ecancer
FEATURING
Shanu Modi
Login to view comments.
Click here to Login